RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/22798687http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/22798687http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/22798687http://www.w3.org/2000/01/rdf-schema#comment"Epoxide hydrolases are a small superfamily of enzymes important for the detoxification of chemically reactive xenobiotic epoxides and for the processing of endogenous epoxides that act as signaling molecules. Here, we report the identification of two human epoxide hydrolases: EH3 and EH4. They share 45% sequence identity, thus representing a new family of mammalian epoxide hydrolases. Quantitative RT-PCR from mouse tissue indicates strongest EH3 expression in lung, skin, and upper gastrointestinal tract. The recombinant enzyme shows a high turnover number with 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid (EET), as well as 9,10-epoxyoctadec-11-enoic acid (leukotoxin). It is inhibited by a subclass of N,N'-disubstituted urea derivatives, including 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, 1-cyclohexyl-3-dodecylurea, and 1-(1-acetylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea, compounds so far believed to be selective inhibitors of mammalian soluble epoxide hydrolase (sEH). Its sensitivity to this subset of sEH inhibitors may have implications on the pharmacologic profile of these compounds. This is particularly relevant because sEH is a potential drug target, and clinical trials are under way exploring the value of sEH inhibitors in the treatment of hypertension and diabetes type II."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.org/dc/terms/identifier"doi:10.1194/jlr.m024448"xsd:string
http://purl.uniprot.org/citations/22798687http://purl.org/dc/terms/identifier"doi:10.1194/jlr.m024448"xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Cronin A."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Cronin A."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Adamska M."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Adamska M."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Zeldin D.C."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Zeldin D.C."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Falck J.R."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Falck J.R."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Hammock B.D."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Hammock B.D."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Di Giallonardo F."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Di Giallonardo F."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Arand M."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Arand M."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Morisseau C."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Morisseau C."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Burgener J."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Burgener J."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Decker M."xsd:string
http://purl.uniprot.org/citations/22798687http://purl.uniprot.org/core/author"Decker M."xsd:string